サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1529764

結合組織疾患の市場規模、シェア、動向分析レポート：疾患別、医薬品別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

Connective Tissue Disease Market Size, Share & Trends Analysis Report By Disease (Rheumatoid Arthritis), By Drug (Pharmaceuticals), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
結合組織疾患の市場規模、シェア、動向分析レポート：疾患別、医薬品別、流通チャネル別、地域別、セグメント別予測、2024年～2030年
出版日: 2024年07月15日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

結合組織病の市場動向

結合組織病の世界市場規模は、2023年に240億4,000万米ドルと推定され、2024年から2030年にかけてCAGR 6.1％で成長すると予測されています。この成長は、これらの疾患の有病率の増加、診断技術と治療アプローチの進歩、効果的な治療に対する需要の高まりに起因しています。関節リウマチ、全身性エリテマトーデス、強皮症などの自己免疫疾患やリウマチ性疾患の罹患率の上昇は、結合組織病（CTD）市場の成長の重要な促進要因です。米国ループス財団によると、約150万人の米国人と500万人以上の人々が何らかのループスに罹患しています。

さらに、世界の高齢化も市場促進要因のひとつです。高齢になると、関節リウマチや強皮症などの自己免疫疾患を発症しやすくなります。この人口統計学的傾向は、結合組織病を患う高齢患者特有のニーズに対応するよう調整された革新的な動向や個別化医療に対する需要を促進しています。製薬会社は、これらの疾患をターゲットとした新規治療法を導入するための研究開発活動に投資しています。

さらに、精密医療とバイオマーカー探索の技術的進歩は、結合組織病の診断と治療の状況を一変させています。自己免疫反応に関与する特定の経路を調節することを目的とした標的療法の出現は、市場の成長を促進しています。例えば、モノクローナル抗体のような生物学的製剤は、CTDの病因に関与する主要分子をターゲットとして開発されており、患者により効果的で安全な治療選択肢を提供しています。こうした技術革新は、患者の転帰と生活の質を改善する個別化ソリューションを提供することで、市場を再形成しています。

結合組織病の世界市場セグメンテーションレポート

本レポートでは、世界、地域、国レベルでの収益成長を予測し、2018年から2030年までの各サブセグメントにおける最新の業界動向の分析を提供しています。この調査において、Grand View Research社は世界の結合組織病市場レポートを疾患、薬剤、流通チャネル、地域に基づいてセグメント化しています：

  • 結合組織疾患の展望（売上高、2018年～2030年）。
  • 関節リウマチ（RA）。
  • 全身性エリテマトーデス（SLE）。
  • 強皮症。
  • 多発性筋炎。
  • 皮膚筋炎。
  • シェーグレン症候群。
  • 混合結合組織病（MCTD）。
  • 未分化結合組織病（UCTD）。
  • その他の結合組織病。
  • 結合組織病治療薬の展望（売上高、2018年～2030年）。
  • 医薬品。

非ステロイド性抗炎症薬（NSAIDs）

疾患修飾性抗リウマチ薬（DMARDs）

コルチコステロイド

その他の医薬品

  • バイオ医薬品

生物製剤

TNF阻害剤

IL-6阻害剤

B細胞阻害剤

T細胞阻害剤

その他の生物製剤

バイオシミラー

  • 結合組織病流通チャネルの展望（売上高、2018年～2030年）。
  • 病院薬局。
  • 小売薬局。
  • オンライン薬局。
  • 地域別展望（収益、2018～2030年）。
  • 北米。

米国。

カナダ

メキシコ

  • 欧州

英国

ドイツ

フランス

イタリア

スペイン

デンマーク

スウェーデン

ノルウェー

  • アジア太平洋

日本

中国

インド

オーストラリア

韓国

タイ

  • ラテンアメリカ

ブラジル

アルゼンチン

  • 中東・アフリカ

南アフリカ

サウジアラビア

アラブ首長国連邦

クウェート

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 結合組織疾患市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場牽引要因分析
    • 市場抑制要因分析
  • 結合組織疾患市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析
    • パイプライン分析

第4章 結合組織疾患市場：疾患推定・動向分析

  • 世界の結合組織疾患市場：疾患ダッシュボード
  • 世界の結合組織疾患市場：疾患分析
  • 疾患別、収益別、世界の結合組織疾患市場
  • 関節リウマチ（RA）
  • 全身性エリテマトーデス（SLE）
  • 強皮症
  • 多発性筋炎
  • 皮膚筋炎
  • シェーグレン症候群
  • 混合性結合組織病（MCTD）
  • 未分化結合組織疾患（UCTD）
  • その他の結合組織疾患

第5章 結合組織疾患市場：医薬品の推定・動向分析

  • 世界の結合組織疾患市場：医薬品ダッシュボード
  • 世界の結合組織疾患市場：医薬品変動分析
  • 医薬品別、収益
  • 医薬品
  • バイオ医薬品

5.5.2.2.1.1. TNF阻害剤市場推計・予測2018年～2030年

5.5.2.3.1.1. IL-6阻害剤市場推計・予測2018年～2030年

5.5.2.4.1.1. B細胞阻害剤市場推計・予測2018年～2030年

5.5.2.5.1.1. T細胞阻害剤市場推計・予測2018年～2030年

5.5.2.6.1.1.その他の生物製剤市場推計・予測2018年～2030年

  • バイオシミラー
    • バイオシミラー市場推計・予測2018～2030年

第6章 結合組織疾患市場：流通チャネルの推定・動向分析

  • 世界の結合組織疾患市場：流通チャネルダッシュボード
  • 世界の結合組織疾患市場：流通チャネル変動分析
  • 流通チャネル別、収益
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 結合組織疾患市場：疾患、医薬品、流通チャネル別の地域推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 企業/競合の分類
  • ベンダー情勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market share analysis, 2023
    • AbbVie, Inc.
    • Amgen, Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson &Johnson Services, Inc.
    • Lily
    • Novartis AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.
    • UCB SA
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 4 North America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 5 North America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 7 U.S. Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 8 U.S. Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 10 Canada Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 11 Canada Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 13 Mexico Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 14 Mexico Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 17 Europe Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 18 Europe Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 20 Germany Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 21 Germany Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 23 UK Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 24 UK Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 26 France Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 27 France Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 29 Italy Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 30 Italy Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 32 Spain Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 33 Spain Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 35 Denmark Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 36 Denmark Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 38 Sweden Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 39 Sweden Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 41 Norway Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 42 Norway Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 48 China Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 49 China Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 51 Japan Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 52 Japan Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 54 India Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 55 India Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 57 South Korea Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 58 South Korea Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 60 Australia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 61 Australia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 63 Thailand Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 64 Thailand Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 67 Latin America Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 68 Latin America Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 70 Brazil Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 71 Brazil Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 73 Argentina Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 74 Argentina Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Connective Tissue Disease market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 77 MEA Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 78 MEA Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 80 South Africa Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 81 South Africa Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 86 UAE Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 87 UAE Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Connective Tissue Disease market, by disease, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Connective Tissue Disease market, by drug, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Connective Tissue Disease market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Connective Tissue Disease market: market outlook
  • Fig. 14 Connective Tissue Disease competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Connective Tissue Disease market driver impact
  • Fig. 18 Connective Tissue Disease market restraint impact
  • Fig. 19 Connective Tissue Disease market: Disease movement analysis
  • Fig. 20 Connective Tissue Disease market: Disease outlook and key takeaways
  • Fig. 21 Rheumatoid Arthritis (RA) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Systemic Lupus Erythematosus (SLE) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Scleroderma market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Polymyositis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Dermatomyositis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Sjogren's Syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Mixed Connective Tissue Disease (MCTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Other connective tissue diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Connective Tissue Disease market: Drug movement analysis
  • Fig. 31 Connective Tissue Disease market: Drug outlook and key takeaways
  • Fig. 32 Pharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Biopharmaceuticals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 TNF Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 IL-6 Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 B-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 T-cell Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other Biologics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Biosimilars market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Connective Tissue Disease market: Distribution channel movement analysis
  • Fig. 46 Connective Tissue Disease market: Distribution channel outlook and key takeaways
  • Fig. 47 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Global Connective Tissue Disease market: Regional movement analysis
  • Fig. 51 Global Connective Tissue Disease market: Regional outlook and key takeaways
  • Fig. 52 Global Connective Tissue Disease market share and leading players
  • Fig. 53 North America, by country
  • Fig. 54 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. key country dynamics
  • Fig. 56 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Canada key country dynamics
  • Fig. 58 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Mexico key country dynamics
  • Fig. 60 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 UK key country dynamics
  • Fig. 63 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Germany key country dynamics
  • Fig. 65 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 France key country dynamics
  • Fig. 67 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Italy key country dynamics
  • Fig. 69 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Spain key country dynamics
  • Fig. 71 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Denmark key country dynamics
  • Fig. 73 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Sweden key country dynamics
  • Fig. 75 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Norway key country dynamics
  • Fig. 77 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 China key country dynamics
  • Fig. 80 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Japan key country dynamics
  • Fig. 82 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 India key country dynamics
  • Fig. 84 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Thailand key country dynamics
  • Fig. 86 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 South Korea key country dynamics
  • Fig. 88 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Australia key country dynamics
  • Fig. 90 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Brazil key country dynamics
  • Fig. 93 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Argentina key country dynamics
  • Fig. 95 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 South Africa key country dynamics
  • Fig. 98 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Saudi Arabia key country dynamics
  • Fig. 100 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 UAE key country dynamics
  • Fig. 102 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Kuwait key country dynamics
  • Fig. 104 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Market share of key market players - Connective Tissue Disease market
目次
Product Code: GVR-4-68040-348-8

Connective Tissue Disease Market Trends

The global connective tissue disease market size was estimated at USD 24.04 billion in 2023 and is expected to grow at a CAGR of 6.1% from 2024 to 2030. This growth is attributed to the increasing prevalence of these diseases, advancements in diagnostic techniques & treatment approaches, and growing demand for effective treatments. The rising incidence of autoimmune and rheumatic disorders, such as rheumatoid arthritis, systemic lupus erythematosus, and scleroderma, is a significant driver for the growth of the connective tissue disease (CTD) market. According to the Lupus Foundation of America,about 1.5 million Americans and more than five million people globally are affected by some type of lupus.

Moreover, the aging population worldwide is another significant driver for the growth of the market. As individuals age, they are more prone to developing autoimmune disorders such as rheumatoid arthritis and scleroderma, both of which fall under the category of connective tissue disease. This demographic trend fuels the demand for innovative therapies and personalized medicine approaches tailored to address the specific needs of elderly patients with connective tissue diseases. Pharmaceutical companies invest in research and development activities to introduce novel treatments targeting these conditions.

Furthermore, technological advancements in precision medicine and biomarker discovery are revolutionizing the diagnosis and treatment landscape for connective tissue diseases. The emergence of targeted therapies that aim to modulate specific pathways involved in autoimmune responses is propelling market growth. For instance, biologics such as monoclonal antibodies are being developed to target key molecules implicated in CTD pathogenesis, offering patients more effective and safer treatment options. These innovations are reshaping the market by providing personalized solutions that improve patient outcomes and quality of life.

Global Connective Tissue Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global connective tissue disease market report on the basis of disease, drug, distribution channel, region:

  • Connective Tissue Disease Outlook (Revenue, USD Million, 2018 - 2030)
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)
  • Scleroderma
  • Polymyositis
  • Dermatomyositis
  • Sjogren's Syndrome
  • Mixed Connective Tissue Disease (MCTD)
  • Undifferentiated Connective Tissue Disease (UCTD)
  • Other connective tissue disease
  • Connective Tissue Disease Drug Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceuticals

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Corticosteroids

Other Pharmaceuticals

  • Biopharmaceuticals

Biologics

TNF Inhibitors

IL-6 Inhibitors

B-cell Inhibitors

T-cell Inhibitors

Other Biologics

Biosimilars

  • Connective Tissue Disease Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

  • Latin America

Brazil

Argentina

  • Middle East and Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Drug outlook
    • 2.2.3. Distribution Channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Connective Tissue Disease Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of connective tissue diseases
      • 3.2.1.2. Aging Population
      • 3.2.1.3. Technological advancements
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment cost
  • 3.3. Connective Tissue Disease Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Connective Tissue Disease Market: Disease Estimates & Trend Analysis

  • 4.1. Global Connective Tissue Disease Market: Disease Dashboard
  • 4.2. Global Connective Tissue Disease Market: Disease Analysis
  • 4.3. Global Connective Tissue Disease Market by Disease, Revenue
  • 4.4. Rheumatoid Arthritis (RA)
    • 4.4.1. Rheumatoid Arthritis (RA) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Systemic Lupus Erythematosus (SLE)
    • 4.5.1. Systemic Lupus Erythematosus (SLE) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Scleroderma
    • 4.6.1. Scleroderma market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Polymyositis
    • 4.7.1. Polymyositis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Dermatomyositis
    • 4.8.1. Dermatomyositis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Sjogren's Syndrome
    • 4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Mixed Connective Tissue Disease (MCTD)
    • 4.10.1. Mixed Connective Tissue Disease (MCTD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Undifferentiated Connective Tissue Disease (UCTD)
    • 4.11.1. Undifferentiated Connective Tissue Disease (UCTD) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.12. Other connective tissue disease
    • 4.12.1. Other connective tissue disease market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Connective Tissue Disease Market: Drug Estimates & Trend Analysis

  • 5.1. Global Connective Tissue Disease Market: Drug Dashboard
  • 5.2. Global Connective Tissue Disease Market: Drug Movement Analysis
  • 5.3. Global Connective Tissue Disease Market Estimates and Forecasts, By Drug, Revenue (USD Million)
  • 5.4. Pharmaceuticals
    • 5.4.1. Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
      • 5.4.2.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
      • 5.4.3.1. Disease-Modifying Anti-Rheumatic Drugs (DMARDs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Corticosteroids
      • 5.4.4.1. Corticosteroids market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Other Pharmaceuticals
      • 5.4.5.1. Other Pharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Biopharmaceuticals
    • 5.5.1. Biopharmaceuticals market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.5.2. Biologics
      • 5.5.2.1. Biologics market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.5.2.2. TNF Inhibitors

5.5.2.2.1.1. TNF Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.3. IL-6 Inhibitors

5.5.2.3.1.1. IL-6 Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.4. B-cell Inhibitors

5.5.2.4.1.1. B-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.5. T-cell inhibitors

5.5.2.5.1.1. T-cell Inhibitors market estimates and forecasts 2018 to 2030 (USD Million)

      • 5.5.2.6. Other Biologics

5.5.2.6.1.1. Other Biologics market estimates and forecasts 2018 to 2030 (USD Million)

  • 5.6. Biosimilars
    • 5.6.1. Biosimilars market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Connective Tissue Disease Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Connective Tissue Disease Market: Distribution Channel Dashboard
  • 6.2. Global Connective Tissue Disease Market: Distribution Channel Movement Analysis
  • 6.3. Global Connective Tissue Disease Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Online Pharmacies
    • 6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Connective Tissue Disease Market: Regional Estimates & Trend Analysis by Disease, Drug, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key customers
    • 8.2.3. Key company market share analysis, 2023
    • 8.2.4. AbbVie, Inc.
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Amgen, Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Boehringer Ingelheim International GmbH
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Bristol-Myers Squibb Company
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. F. Hoffmann-La Roche Ltd.
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Johnson & Johnson Services, Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Lily
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Novartis AG
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Pfizer Inc.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives
    • 8.2.13. Regeneron Pharmaceuticals Inc.
      • 8.2.13.1. Company overview
      • 8.2.13.2. Financial performance
      • 8.2.13.3. Product benchmarking
      • 8.2.13.4. Strategic initiatives
    • 8.2.14. UCB S.A.
      • 8.2.14.1. Company overview
      • 8.2.14.2. Financial performance
      • 8.2.14.3. Product benchmarking
      • 8.2.14.4. Strategic initiatives